Cannabis Stock Gainers And Losers From August 5, 2019
Gainers
- iAnthus Capital Holdings (OTC:ITHUF) shares rose 0.05%, to close at $2.90.
- Akerna (NASDAQ:KERN) shares rose 0.2%, to close at $9.92.
Losers
- Aurora Cannabis (NYSE:ACB) shares tumbled by 2.29%, eventually closing at $6.18.
- Aphria (NYSE:APHA) shares fell 4.09% to close at $7.03.
- Canopy Growth (NYSE:CGC) shares tumbled by 4.07%, eventually closing at $31.38.
- Cronos Group (NASDAQ:CRON) shares tumbled by 3.03%, eventually closing at $13.42, although one analyst believes it will break out in coming quarters.
- CannTrust Holdings (NYSE:CTST) shares dropped by 3.96%, to close at $2.18.
- Curaleaf Holdings (OTC:CURLF) shares dropped by 4.93%, to close at $7.45.
- Greenlane Holdings (NASDAQ:GNLN) shares dropped by 2.0%, to close at $7.85.
- GW Pharmaceuticals (NASDAQ:GWPH) shares dropped by 2.83%, to close at $151.31.
- HEXO (NYSE:HEXO) shares tumbled by 4.1%, eventually closing at $4.21.
- India Globalization Cap (AMEX:IGC) shares fell 5.83% to close at $1.13.
- Innovative Industrial (NYSE:IIPR) shares tumbled by 3.48%, eventually closing at $99.14.
- MedMen Enterprises (OTC:MMNFF) shares dropped by 0.9%, to close at $1.99.
- New Age Beverages (NASDAQ:NBEV) shares dropped by 5.6%, to close at $3.54.
- OrganiGram Holdings (NASDAQ:OGI) shares fell 3.29% to close at $5.58.
- Pyxus International (NYSE:PYX) shares fell 3.61% to close at $13.88.
- Tilray (NASDAQ:TLRY) shares tumbled by 2.2%, eventually closing at $42.29.
- Therapix Biosciences (NASDAQ:TRPX) shares tumbled by 5.53%, eventually closing at $2.39.
- cbdMD (AMEX:YCBD) shares tumbled by 1.09%, eventually closing at $4.53.
- Zynerba Pharmaceuticals (NASDAQ:ZYNE) shares fell 3.64% to close at $9.79.
Related Links:
'The Next Evolution Of Cannabis Financing': Inside Harvest Health & Rec's $225-Million Loan
'Evolving Interests And Values': 3 Takeaways From The Inaugural Apex Millennial 100 Report
Switzerland-Based SIX Launches Securities Monitoring For Marijuana-Related Businesses
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.